Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? Pro position

Current Hypertension Reports

Volumn 4, Issue 4, 2002, Pages 307-310

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AFRICAN AMERICAN; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; ETHNOLOGY; HUMAN; NEGRO; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 0036691148     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-996-0009-8     Document Type: Article

References (12)

1. Weinberger MH: Salt sensitivity of blood pressure in humans. Hypertension 1996, 27: 481-490.
2. He FJ, Markandu ND, Sagnella GA, MacGregor GA: Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 1998, 32: 820-824.
3. Stein CM, Lang CC, Nelson R, et al.: Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharm Ther 1998, 62: 436-443.
4. Materson BJ, Reda DJ, Cushman WC, et al.: Single-drug therapy for hypertension in men - a comparison of six antihypertensive agents with placebo. N Engl J Med 1993, 328: 914-921.
5. Dries DL, Exner DV, Gersh BJ, et al.: Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999, 340: 609-616.
6. Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 1986, 314: 1547-1552.
7. Carson P, Ziesche S, Johnson G, Cohn JN, for the Vasodilator-Heart Failure Trial Study Group: Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Card Fail 1999, 5: 178-187.
8. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325: 303-310.
9. Exner DV, Dries DL, Domanski MJ, Cohn JN: Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344: 1351-1357.
10. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327: 685-691.
11. Franciosa JA, Taylor AL, Cohn JN, et al., for the A-HeFT Investigators: African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002, In press.
12. The Beta-Blocker Evaluation of Survial Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344: 1659-1667.